AChE inhibitors, the most used drugs of AD treatment to slow neurodegeneration, induce a synaptic increase in ACh and a direct stimulation of ACh receptors, and may affect the inflammatory activity of cells participating in AD-associated inflammation, inducing a Th1 to Th2 switch [93] and decreasing inflammation by a dose-dependent reduction in inflammatory cytokine levels [94,95]. Here, ACHE is linked to Alzheimer disease.